Spero therapeutics tebipenem pivoxil hydrobromide phase 3 data published in the new england journal of medicine

Cambridge, mass., april 06, 2022 (globe newswire) -- spero therapeutics, inc. (nasdaq: spro) today announced publication in the new england journal of medicine (nejm) of the results from the phase 3 adapt-po clinical trial for its investigational oral carbapenem antibiotic, tebipenem pivoxil hydrobromide (tebipenem hbr). the paper, titled “oral tebipenem pivoxil hydrobromide in complicated urinary tract infection,” is available online at the new england journal of medicine (nejm).
SPRO Ratings Summary
SPRO Quant Ranking